Pharmaceuticals, Biotechnology and Life Sciences
During the COVID-19 crisis, it is critical for companies in the pharmaceutical market to take calculative and well-executed measures to ensure business continuity in the long run.
Kala Pharmaceuticals has resubmitted its New Drug Application to the FDA for Eysuvis, its product candidate to treat dry eye disease.
Adare Pharmaceuticals has bought a technology company Orbis Biosciences, aiming to enhance its own Pharmaceutical Technologies business, creating products for global pharma, animal health and OTC markets.
Truxima, the only US biosimilar to Rituxan, is also now available for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).
AbCellera’s world-leading drug discovery technology identifies antibodies for potential use in drugs to treat and prevent COVID-19 got cash support from Canadian Government of $175.6 million.
Gilead get’s authorization of emergency use of Remdesivir to treat hospitalized patients with severe COVID-19 disease in the United States.
Revance, Mylan Biosimilar to Botox postpon program decision to aftr April
Moderna has engaged with Lonza to work on its novel coronavirus vaccine, with a goal to enable manufacturing of up to 1 billion doses per year, noting that technology transfer is expected to begin in June 2020.
Shionogis’ Fetcroja (cefiderocol) in the end of April 2020 received European Commission (EC) marketing authorisation for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options.
ALBANY, N.Y.–(BUSINESS WIRE)–AMRI today announced its ongoing commitment to do its part in support of public health needs amidst the…